{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:40:35Z","timestamp":1786592435765,"version":"build-2736575974"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"US Government","award":["MCDC-18-06-16-005 under Other Transaction number W15QKN-16-9-1002"],"award-info":[{"award-number":["MCDC-18-06-16-005 under Other Transaction number W15QKN-16-9-1002"]}]},{"name":"US Government","award":["MCDC-18-06-16-005 under Other Transaction number W15QKN-16-9-1002"],"award-info":[{"award-number":["MCDC-18-06-16-005 under Other Transaction number W15QKN-16-9-1002"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,1,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              LPC-233 (a.k.a. VB-233) is a potent antibiotic targeting the essential enzyme LpxC in Gram-negative bacteria. We present herein the pharmacokinetics and pharmacodynamics data of LPC-233 for treating murine infections caused by\n              <jats:italic>Burkholderia pseudomallei<\/jats:italic>\n              , a potential biodefense pathogen. A range of doses was evaluated in a post-aerosol exposure model of\n              <jats:italic>B. pseudomallei<\/jats:italic>\n              -infected mice. After the aerosol challenge with the\n              <jats:italic>B. pseudomallei<\/jats:italic>\n              strain K96243, treatment was initiated with 10, 30, or 90 mg\/kg of LPC-233 orally every 12 h (q12h) or 90 mg\/kg intraperitoneally q12h for 14 days. A vehicle-control arm and a positive-control arm consisting of one of the recommended standards of care, ceftazidime (150 mg\/kg, q6h) injected subcutaneously, were included. LPC-233 significantly and dose-dependently rescued mice from\n              <jats:italic>B. pseudomallei<\/jats:italic>\n              infection in comparison with the vehicle (\n              <jats:italic>P<\/jats:italic>\n              &lt; 0.0001). At dose levels of 30 mg\/kg or higher, the survival rate with LPC-233 was significantly higher than that from the ceftazidime arm (\n              <jats:italic>P<\/jats:italic>\n              range: 0.001\u20130.05). LPC-233 reversed the murine body weight loss caused by the\n              <jats:italic>B. pseudomallei<\/jats:italic>\n              infection more rapidly than ceftazidime did, suggesting that it is a faster-acting antibiotic in this dosing regimen. Despite the outstanding survival advantage of LPC-233 over ceftazidime, no significant differences in tissue burdens (liver, lung, spleen, and blood) were observed among any of the treatment groups surviving to the termination of the experiment, suggesting that similar to commercial antibiotics, LPC-233 treatment for lethal\n              <jats:italic>B. pseudomallei<\/jats:italic>\n              infection may likely require both an acute phase of intensive treatment and an eradication phase of prolonged treatment.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.01295-24","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T14:04:43Z","timestamp":1734098683000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant\n            <i>Burkholderia pseudomallei<\/i>\n            in a murine infection model"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4746-4892","authenticated-orcid":true,"given":"Henry S.","family":"Heine","sequence":"first","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bret K.","family":"Purcell","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton","family":"Duncan","sequence":"additional","affiliation":[{"name":"Valanbio Therapeutics Inc.","place":["Raleigh, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Miller","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Craig","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Chase","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Honour","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vicchiarelli","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-7332","authenticated-orcid":true,"given":"George L.","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida","place":["Orlando, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7823-3416","authenticated-orcid":true,"given":"Pei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Duke University School of Medicine","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.107"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030789"},{"key":"e_1_3_4_4_2","first-page":"17","article-title":"Resistance pattern of Burkholderia pseudomallei from clinical isolates at Dr. Saiful Anwar general hospital, Malang-Indonesia","volume":"1","author":"Irmawanti-Rahayu S","year":"2014","unstructured":"Irmawanti-Rahayu S, Noorhamdani AS, Santoso S. 2014. Resistance pattern of Burkholderia pseudomallei from clinical isolates at Dr. Saiful Anwar general hospital, Malang-Indonesia. J Clin Microbiol Infect Dis 1:17\u201320.","journal-title":"J Clin Microbiol Infect Dis"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.03.022"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00472-08"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.71.110601.135414"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-060713-035600"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2016.11.014"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.0c00880"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025304"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1360282"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115326"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf5668"},{"key":"e_1_3_4_15_2","volume-title":"Methods for dlution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Institute CaLS","year":"2018","unstructured":"Institute CaLS. 2018. Methods for dlution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.6.1793-1799.2002"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05417-11"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.447607"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0891-5520(03)00059-x"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00834-19"},{"key":"e_1_3_4_21_2","volume-title":"Pharmacokinetics of antimicrobial agents: principles, methods, applications ecomed","author":"Tozuka Z","year":"1993","unstructured":"Tozuka Z. 1993. Penicillines-parameters. In kuemmereHP, Murakawa T (ed), Pharmacokinetics of antimicrobial agents: principles, methods, applications ecomed."},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208277"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11101442"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030506"},{"key":"e_1_3_4_25_2","unstructured":"Marchand C Miller L Halasohoris S Hersjfield J Serio AW Cirz R Heine H. 2013. In vitro activity of ACHN-975 against biodefense pathogens abstr ICAAC Denver USA."},{"key":"e_1_3_4_26_2","volume-title":"Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria","author":"CLSI","year":"2010","unstructured":"CLSI. 2010. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_4_27_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standard Institute, Wayne, PA."},{"key":"e_1_3_4_28_2","volume-title":"Guide for the care and use of laboratory animals","year":"1996","unstructured":"Guide for the care and use of laboratory animals. 1996. Washington, D.C."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2003.07.001"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1947.150.1.70"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1201\/9781420038118.ch5"},{"key":"e_1_3_4_32_2","volume-title":"ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software","author":"D\u2019Argenio DZ","year":"2009","unstructured":"D\u2019Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1109\/CBMS.2001.941750"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkae241"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01295-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01295-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T14:02:36Z","timestamp":1738332156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01295-24"}},"subtitle":[],"editor":[{"given":"Jared A.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,31]]}},"alternative-id":["10.1128\/aac.01295-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01295-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"2024-08-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01295-24"}}